98%
921
2 minutes
20
Focused ultrasound (FUS) blood brain barrier disruption (BBBD) permits the noninvasive, targeted, and repeatable delivery of drugs to the brain. FUS BBBD also elicits secondary responses capable of augmenting immunotherapies, clearing amyloid-β and hyperphosphorylated tau, and driving neurogenesis. Leveraging these secondary effects will benefit from an understanding of how they correlate to the magnitude of FUS BBBD and are differentially affected by the mechanical and biochemical stimuli imparted during FUS BBBD. We aggregated 75 murine transcriptomes in a multiple regression framework to identify genes expressed in proportion to biochemical (i.e. contrast MR image enhancement (CE)) or mechanical (i.e. harmonic acoustic emissions from MB-activation (MBA)) stimuli associated with FUS BBBD. Models were constructed to control for potential confounders, such as sex, anesthesia, and sequencing batch. MBA and CE differentially predicted expression of 1,124 genes 6 h or 24 h later. While there existed overlap in the transcripts correlated with MBA vs CE, MBA was principally predictive of expression of genes associated with endothelial reactivity while CE chiefly predicted sterile inflammation gene sets. Over-representation analysis identified transcripts not previously linked to BBBD, including actin filament organization, which is likely important for BBB recovery. Transcripts and pathways associated with neurogenesis, microglial activation, and amyloid-β clearance were significantly correlated to BBBD metrics. The secondary effects of BBBD may have the potential to be tuned by modulating FUS parameters during BBBD, and MBA and CE may serve as independent predictors of transcriptional reactions in the brain.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8581408 | PMC |
http://dx.doi.org/10.7150/thno.65064 | DOI Listing |
Sci Rep
May 2025
Medical Device Development Center, Daegu-Gyeongbuk Medical Innovation Foundation (K- MEDIhub), Daegu, South Korea.
Focused ultrasound (FUS) with magnetic resonance imaging (MRI) guidance (MRgFUS) has emerged as a promising technique for enhancing drug delivery to the brain. Through the controlled oscillation of gas-encased microbubbles, FUS temporarily modulates the integrity of tight junctions, inducing localized blood-brain barrier disruption (BBBD) and allowing targeted drug passage. Aducanumab (ADU) has demonstrated efficacy in reducing amyloid pathology, yet its clinical application remains limited by the restrictive nature of the blood-brain barrier (BBB).
View Article and Find Full Text PDFSci Rep
February 2025
College of IT Convergence, Department of Biomedical Device, Gachon University, 1342, Seongnam-daero, Sujeong-gu, 1342, Seongnam, 13120, Gyeonggi, Republic of Korea.
Focused ultrasound (FUS) has emerged as a promising technique for temporarily disrupting the blood-brain barrier (BBB) and blood-tumor barrier (BTB) to enhance the delivery of therapeutic agents. Despite its potential, optimizing FUS to maximize drug delivery while minimizing adverse effects remains a significant challenge. In this study, we evaluated a novel FUS protocol that incorporates additional FUS stimulation without microbubbles (MBs) ("FUS protocol") prior to conventional BBB disruption with MBs ("BBBD protocol") in a rat brain tumor model (n = 35).
View Article and Find Full Text PDFJ Clin Neurosci
October 2024
Department of Neurological Surgery, University of Virginia, Charlottesville, USA. Electronic address:
Background: This scoping review aims to comprehensively review the available literature on the safety and efficacy of focused ultrasound (FUS) for blood-brain barrier disruption (BBBD) in patients with high-grade gliomas, including glioblastoma (GBM). High-grade gliomas pose significant challenges in neuro-oncology due to their aggressiveness and intricate location, often limiting the efficacy of traditional treatments. FUS offers a promising approach by transiently disrupting the blood-brain barrier, thereby facilitating enhanced drug delivery to tumor cells while minimizing systemic side effects.
View Article and Find Full Text PDFCurr Oncol Rep
March 2024
Department of Neurological Surgery, Indiana University School of Medicine, Indianapolis, IN, USA.
Purpose Of Review: To review relevant advances in the past half-decade in the treatment of primary brain tumors via modification of blood-brain barrier (BBB) permeability.
Recent Findings: BBB disruption is becoming increasingly common in the treatment of primary brain tumors. Use of mannitol in BBB disruption for targeted delivery of chemotherapeutics via superselective intra-arterial cerebral infusion (SIACI) is the most utilized strategy to modify the BBB.
STAR Protoc
March 2024
Department of Biomedical Engineering, Tel Aviv University, Tel Aviv, Israel; Sagol School of Neuroscience, Tel Aviv University, Tel Aviv, Israel. Electronic address: